HC Wainwright Issues Negative Estimate for Cybin Earnings

Cybin Inc. (NYSE:CYBN) – Stock analysts at HC Wainwright cut their Q3 2025 EPS estimates for Cybin in a research note issued to investors on Tuesday, November 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.53) per share for the quarter, down from their previous forecast of ($0.38). HC Wainwright has a “Buy” rating and a $190.00 price target on the stock. The consensus estimate for Cybin’s current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Cybin’s Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.63) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($2.69) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at $4.22 EPS and FY2029 earnings at $9.57 EPS.

CYBN has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cybin in a report on Wednesday, July 31st. Canaccord Genuity Group dropped their target price on shares of Cybin from $96.00 to $86.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

Cybin Stock Down 3.5 %

NYSE:CYBN opened at $9.80 on Thursday. The firm has a market capitalization of $195.92 million, a P/E ratio of -1.44 and a beta of 0.38. Cybin has a one year low of $6.50 and a one year high of $21.66. The stock has a 50-day moving average price of $9.57.

Institutional Trading of Cybin

A number of institutional investors and hedge funds have recently made changes to their positions in CYBN. PEAK6 Investments LLC acquired a new stake in Cybin in the first quarter worth about $95,000. Sanctuary Advisors LLC bought a new stake in shares of Cybin during the 2nd quarter worth about $36,000. AdvisorShares Investments LLC lifted its stake in shares of Cybin by 13.4% in the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company’s stock worth $494,000 after acquiring an additional 220,403 shares during the period. Ikarian Capital LLC bought a new position in shares of Cybin in the first quarter valued at approximately $5,770,000. Finally, Rosalind Advisors Inc. increased its stake in shares of Cybin by 38.3% during the second quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock valued at $5,230,000 after acquiring an additional 5,340,000 shares during the period. 17.94% of the stock is currently owned by institutional investors and hedge funds.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.